Parker Waichman Alonso LLP Files Suit Against General Electric Company on Behalf of a Man Who Developed Nephrogenic Systemic Fibrosis (NSF) from Contrast Agen...( GREAT NECK N.Y. March 5 /- Parker...),Health

GREAT NECK, N.Y., March 5 /PRNewswire/ -- Parker Waichman Alonso LLP announces that it has filed suit on behalf of a man diagnosed with Nephrogenic Systemic Fibrosis (NSF) after receiving two injections of Omniscan, a gadolinium contrast dye manufactured by General Electric Company, its subsidiaries and Novation LLC. NSF is a debilitating, often fatal disease that robs patients of their mobility. NSF is a condition that affects patients with pre-existing kidney disease who have been exposed to gadolinium contrast dyes such as Omniscan. Symptoms of NSF include thickening and hardening of the skin, joint problems, muscle weakness and eye discoloration. The lawsuit was filed in the US District Court for the Eastern District of Pennsylvania (Docket Number: 2:08-cv-1060)

Zbigniew Marcinczyk, a resident of Philadelphia and a patient with pre-existing kidney disease, received two injections of gadolinium contrast dye in September and December 2005. Representatives from Holy Redeemer Hospital and the University of Pennsylvania Hospital in Philadelphia have confirmed that the gadolinium contrast dye administered to Marcinczyk was Omniscan. Shortly after the administration of Omniscan, Marcinczyk developed and continues to suffer from the severe, debilitating and progressive fibrotic changes associated with NSF. This has permanently disabled, disfigured and severely impaired the plaintiff.

The lawsuit alleges that the chemical make-up of Omniscan makes it more likely that gadolinium will become free within the bodies of recipients, thereby making it more likely that kidney patients will develop NSF. The lawsuit further alleges that Omniscan is defective, and that the defendants failed to adequately test Omniscan and failed to warn patients about its potential to cause NSF. In September 2007, the Food & Drug Administration (FDA) asked the manufacturers of gadolinium contrast dyes to add a black box warning to the product labels about its association with N
'/>"/>